Over the last 7 days, the market has dropped 1.4%, but it remains up 17% over the past year, with earnings expected to grow by 18% per annum over the next few years. For those looking to invest in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer surprising value when they have solid financial foundations. In this article, we explore several penny stocks that demonstrate financial strength and may have long-term potential.

Here we highlight a subset of our preferred stocks from the screener.

Anixa Biosciences (ANIX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Anixa Biosciences, Inc. is a biotechnology company that develops therapies and vaccines targeting critical unmet needs in oncology, with a market cap of $115.68 million.

Operations: Anixa Biosciences, Inc. has not reported any revenue segments.

Market Cap: $115.68M

Anixa Biosciences, Inc., with a market cap of US$115.68 million, is a pre-revenue biotechnology company focused on oncology therapies and vaccines. The company has made strides in its intellectual property portfolio, recently securing an Australian patent for its breast cancer vaccine technology. Clinical trials are ongoing for both the breast cancer vaccine and FSHR-targeted CAR-T therapy for ovarian cancer, showing promising safety profiles and preliminary efficacy data. Despite being unprofitable, Anixa has reduced losses over the past five years by 3.2% annually and maintains sufficient cash runway to support continued development efforts without significant shareholder dilution.

Organogenesis Holdings (ORGO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care and surgical and sports medicine markets in the United States, with a market cap of $337.13 million.

Operations: The company's revenue is derived entirely from its Regenerative Medicine segment, totaling $514.70 million.

Market Cap: $337.13M

Organogenesis Holdings Inc., with a market cap of US$337.13 million, is navigating challenges as it remains unprofitable and faces declining revenues, recently reporting a significant year-over-year drop in first-quarter sales to US$36.25 million. Despite these hurdles, the company has no debt and maintains sufficient cash runway for over three years. Its Biologics License Application for ReNu, aimed at treating knee osteoarthritis, was accepted by the FDA with an action date set for April 2027. Recent index adjustments saw Organogenesis added to several value benchmarks while being dropped from growth indices, reflecting shifts in market perception.

AGNT (AGNT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: AGNT, Inc, along with its subsidiaries, offers cloud-based real estate brokerage services for residential homeowners and homebuyers, with a market cap of $752.60 million.

Operations: AGNT's revenue is primarily derived from North American Realty at $4.67 billion and International Realty at $155.43 million, along with Other Affiliated Services contributing $2.91 million.

Market Cap: $752.6M

AGNT, Inc., with a market cap of US$752.60 million, remains unprofitable with increasing losses over the past five years. Despite this, it reported first-quarter sales of US$1 billion and anticipates second-quarter revenue between US$1.36 billion and US$1.45 billion. The company is debt-free, has stable weekly volatility at 9%, and its short-term assets exceed liabilities by US$117.4 million. AGNT recently underwent significant changes including a name change from eXp World Holdings and redomestication to Texas, while also facing legal challenges related to class actions in real estate transactions that are pending settlement approval.

Seize The Opportunity

• Access the full spectrum of 324 US Penny Stocks by clicking on this link.
• Want To Explore Some Alternatives? The end of cancer? These 33 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.